By promoting the cytotoxic function of CD8+ T cells, immune checkpoint inhibitor therapy, e.g. programmed cell death protein-1 (PD-1), effectively inhibits tumor growth in renal cell carcinoma. This evidence concerns the gene PDCD1 and hereditary clear cell renal cell carcinoma.